About Orthos

For information on our Board of Directors please click here.

In 2003 Orthos acquired intellectual property rights that allowed it to develop and manufacture a synthetic bone material. This provided the opportunity to focus the business on the development of synthetic, biologically active, tissue engineered products for the restoration of the human skeleton.

In November 2004 Orthos raised new capital and used this to complete accreditation of its quality management system under the medical device regulations (ISO 13485:2003 & ISO9001:2000). In addition they were able to validate its manufacturing processes. These steps led to regulatory approval (CE mark and FDA) for its first product, βGran. βGran is a synthetic osteoconductive scaffold used by orthopaedic surgeons treating voids and defects in the skeleton due to fractures and for other therapeutic surgical techniques in spinal surgery.

This funding also enabled Orthos to complete development of its second proprietary product, Osteoboost, which is complementary to βGran and allows the surgeon to painlessly harvest or extract stem cells found in a patient’s bone marrow using a minimally invasive technique. This ability to harvest bone marrow cells and combine them with a synthetic material to produce a bio-active composite gives the surgeon, for the first time, a real alternative to conventional bone graft surgery.

Regulatory approval for Osteoboost was received for Europe in June 2006 and for the USA in October 2006. The combination of Osteoboost enhancing the effect of βGran clearly differentiates the company’s products in the market place.

New investment has recently been made by existing shareholders and a new investor – Finance Wales. This will enable the company to effectively market its first two products and to launch its new βGel product. This will be achieved by recruiting a sales and marketing team to be led by the recently appointed CEO. In addition, this new investment will allow the company to expand its product range and to achieve regulatory approval for the proposed HiVis and Osteo-Axis products that will facilitate the company’s entry into the massive  (>$2bn) and high growth vertebral compression fracture market.

Click here to see The Board of Directors.